tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
LENZ Therapeutics: Buy Rating Affirmed Amid Successful Early Launch of Vizz and Promising Market Potential
PremiumRatingsLENZ Therapeutics: Buy Rating Affirmed Amid Successful Early Launch of Vizz and Promising Market Potential
29d ago
LENZ Therapeutics Launches FDA-Approved Presbyopia Eye Drop
Premium
Company Announcements
LENZ Therapeutics Launches FDA-Approved Presbyopia Eye Drop
29d ago
Lenz Therapeutics announces U.S. commercial availability of VIZZ
Premium
The Fly
Lenz Therapeutics announces U.S. commercial availability of VIZZ
29d ago
Buy Rating for LENZ Therapeutics: Vizz’s Early FDA Approval and Market Differentiation Drive Growth Potential
PremiumRatingsBuy Rating for LENZ Therapeutics: Vizz’s Early FDA Approval and Market Differentiation Drive Growth Potential
3M ago
Lenz Therapeutics price target raised to $52 from $49 at Citi
Premium
The Fly
Lenz Therapeutics price target raised to $52 from $49 at Citi
3M ago
LENZ Therapeutics Gains FDA Approval for VIZZ Eye Drop
Premium
Company Announcements
LENZ Therapeutics Gains FDA Approval for VIZZ Eye Drop
3M ago
Lenz Therapeutics price target raised to $49 from $45 at Citi
PremiumThe FlyLenz Therapeutics price target raised to $49 from $45 at Citi
3M ago
Lenz Therapeutics Prepares for LNZ100 Launch
Premium
Company Announcements
Lenz Therapeutics Prepares for LNZ100 Launch
3M ago
LENZ Therapeutics: Positioned for Growth with Strategic Global Expansion and Imminent FDA Approval
Premium
Ratings
LENZ Therapeutics: Positioned for Growth with Strategic Global Expansion and Imminent FDA Approval
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100